Hyzaar Articles
US FDA clears Mylan’s generic versions of Hyzaar and Cozaar and Watson’s copy of Lotrel; Watson settles with Endo
18 October 2010
Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development
2 March 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
Merck & Co income still up despite low sales
28 July 2008
ARB switching strategy may not result in long-term savings within a five-year model, says Merck & Co
12 May 2008
EMEA's PDCO issues PIP review opinions
4 February 2008
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
UK parallel traders claim L30M Cozaar/Hyzaar savings for NHS
3 September 2007
Merck & Co's 2nd-qtr 2007 EPS jumps 12%
30 July 2007
Merck & Co's 1st-qtr income climbs 12%
30 April 2007
Merck & Co's 3rd-qtr income down 38% to $904.6 million on flat sales and higher costs
30 October 2006
Merck & Co sees 1st-qtr net income of $1.52B
1 May 2006
Merck & Co beats forecasts; profit up 2%
6 February 2006
Vioxx loss drags on Merck & Co results
22 April 2005
Expanded use for Merck & Co's Hyzaar
16 August 2004
Merck & Co 2nd-qtr profit dips 2%
26 July 2004
UPDATE: Merck & Co strikes $272M Actelion deal
15 December 2003
Merck & Co strikes $272M development deal with Actelion
15 December 2003
Merck & Co strikes $272M Actelion deal
8 December 2003
Cozaar backed for stroke prevention
13 January 2003
Banyu says Proscar still on file in Japan
3 June 2002
Five key products continue to drive Merck & Co sales in 2001
28 January 2002
Merck points to robust pipeline despite near-term profits warning
12 December 2001
Merck & Co turnover up 13% but Vioxx sales are slowing down
19 October 2001
Merck & Co sales up 13% for 3rd qtr
18 October 2001
French price cuts for GSK, Lilly, Merck drugs
16 August 2001
Five drugs push Merck & Co sales up 25%
23 July 2001
Merck & Co sales leap 28%; EPS up 13%
23 April 2001
Sankyo seeks FDA OK for hypertension drug
1 August 2000
Merck & Co posts strong sales growth
25 July 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
1st Launches For Novartis' Exelon And CoDiovan
21 November 1997
Irbesartan To Reach First Markets This Month
3 September 1997
Antihypertensive Sales "Set To Decline"
1 August 1997
Merck's Hyzaar Approved In Canada
23 December 1996
Global Branding Is A Must For Pharmaceuticals
12 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Sanofi's Mid-term Pipeline "One Of The Most Promising
23 October 1995
Merck & Co's Cozaar: share of US ACE market
21 August 1995
Merck pipline report
3 July 1995
First Launch Of Merck's Losartan Combination
15 May 1995
MERCK FILES NDAs FOR COZAAR WORLDWIDE
21 February 1994
Showing 1-72 of 72 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
